KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Total Non-Current Liabilities: 2011-2025

Historic Total Non-Current Liabilities for Arbutus Biopharma (ABUS) over the last 15 years, with Sep 2025 value amounting to $9.2 million.

  • Arbutus Biopharma's Total Non-Current Liabilities fell 63.47% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year decrease of 63.47%. This contributed to the annual value of $24.1 million for FY2024, which is 21.66% down from last year.
  • As of Q3 2025, Arbutus Biopharma's Total Non-Current Liabilities stood at $9.2 million, which was down 2.95% from $9.5 million recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Total Non-Current Liabilities registered a high of $55.6 million during Q1 2022, and its lowest value of $9.2 million during Q3 2025.
  • Its 3-year average for Total Non-Current Liabilities is $26.0 million, with a median of $27.9 million in 2024.
  • Per our database at Business Quant, Arbutus Biopharma's Total Non-Current Liabilities spiked by 336.88% in 2022 and then slumped by 67.92% in 2025.
  • Arbutus Biopharma's Total Non-Current Liabilities (Quarterly) stood at $18.8 million in 2021, then skyrocketed by 157.08% to $48.2 million in 2022, then crashed by 36.14% to $30.8 million in 2023, then fell by 21.66% to $24.1 million in 2024, then crashed by 63.47% to $9.2 million in 2025.
  • Its last three reported values are $9.2 million in Q3 2025, $9.5 million for Q2 2025, and $27.3 million during Q1 2025.